// App-Quantinova.ai

e16502 : Pantoprazole affecting docetaxel resistance pathways via autophagy (PANDORA): a phase II trial in men with castration resistant prostate cancer (mCRPC).

Researchers

Presenter

  • Aaron Richard Hansen

Principal Investigators

  • Ian Tannock

  • Amy Prawira

  • Jennifer J. Knox

  • Arnoud J. Templeton

  • Francisco Vera-Badillo

  • Eric Xueyu Chen

  • Mary-Beth Zavitz

  • Lisa Wang

  • Andrew Evans

  • Susie Tan

  • Brad Wouters

  • Srikala S. Sridhar

  • Anthony M. Joshua

Medical Centers

  • Princess Margaret Cancer Center, Toronto, ON, Canada

  • Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada

  • Calvary Mater Newcastle Hospital, Waratan, Australia

  • Kantonsspital St Gallen, St Gallen, Switzerland

  • Queen's University, Kingston, ON, CA

  • Princess Margaret Cancer Centre University Health Network, Toronto, Ontario, Canada

  • Department of Biostatistics, Princess Margaret Cancer Centre, Toronto, ON, Canada

  • Department of Laboratory Medicine and Pathology, University of Toronto, University Health Network, Toronto, ON, Canada

  • University of Toronto, Toronto, ON, Canada

Locations

  • Canada

  • Switzerland

  • Australia

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • Prostate specific antigen

Drug/Treatment

  • pantoprazole

  • Prednisone

  • Docetaxel

Outcome

  • Unknown

Study Design

  • N/A

Phase

  • II

Study Id's

  • NCT01748500

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved